Literature DB >> 32140282

Exhalation Delivery System: Novel Device for Nasal Polyps Treatment.

Rebecca Chu1.   

Abstract

Nasal polyps are a concern for both adults and children. The treatment of nasal polyps typically is glucocorticoids, both topically and systemically administered. However, patients often experience refractory nasal polyps. A proposed reason for unsatisfactory treatment for the reoccurrence of nasal polyps is because of the drug delivery options through the nose that requires patients to coordinate actuation, head placement, and administration. In addition, many of these delivery systems have shown poor delivery efficiency due to medication depositing into the lungs. To combat these difficulties, Optinose has created an exhalation delivery system that could be used for both liquid and powered medications. Xhance® (fluticasone propionate), which uses this new delivery system, is currently approved for the treatment of nasal polyps in adults. It has shown promising results in adults and is currently undergoing evaluation in pediatric patients. Copyright 2019, Mary Ann Liebert, Inc., publishers.

Entities:  

Keywords:  exhalation delivery system; inflammation; nasal delivery; nasal polyps

Year:  2019        PMID: 32140282      PMCID: PMC7057051          DOI: 10.1089/ped.2019.1066

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol Pulmonol        ISSN: 2151-321X            Impact factor:   1.349


  12 in total

1.  The 'best method' of topical nasal drug delivery: comparison of seven techniques.

Authors:  P Merkus; F A Ebbens; B Muller; W J Fokkens
Journal:  Rhinology       Date:  2006-06       Impact factor: 3.681

Review 2.  Devices for aerosol delivery to treat sinusitis.

Authors:  Beth L Laube
Journal:  J Aerosol Med       Date:  2007

3.  Nasal polyposis.

Authors:  G A Brown
Journal:  Postgrad Med J       Date:  1969-10       Impact factor: 2.401

Review 4.  Nasal anatomy, physiology, and function.

Authors:  N Geurkink
Journal:  J Allergy Clin Immunol       Date:  1983-08       Impact factor: 10.793

5.  NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis.

Authors:  Donald A Leopold; David Elkayam; John C Messina; Colette Kosik-Gonzalez; Per G Djupesland; Ramy A Mahmoud
Journal:  J Allergy Clin Immunol       Date:  2018-06-19       Impact factor: 10.793

6.  Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump.

Authors:  Per Gisle Djupesland; Arne Skretting
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2012-01-17       Impact factor: 2.849

7.  Nasal polyposis in children.

Authors:  D Caimmi; E Matti; G Pelizzo; A Marseglia; S Caimmi; E Labò; A Licari; F Pagella; A M Castellazzi; A Pusateri; G B Parigi; G L Marseglia
Journal:  J Biol Regul Homeost Agents       Date:  2012 Jan-Mar       Impact factor: 1.711

8.  Nasal polyps in children.

Authors:  V L Schramm; M Z Effron
Journal:  Laryngoscope       Date:  1980-09       Impact factor: 3.325

9.  EXHANCE-12: 1-year study of the exhalation delivery system with fluticasone (EDS-FLU) in chronic rhinosinusitis.

Authors:  James N Palmer; Kraig W Jacobson; John C Messina; Colette Kosik-Gonzalez; Per G Djupesland; Ramy A Mahmoud
Journal:  Int Forum Allergy Rhinol       Date:  2018-06-01       Impact factor: 3.858

10.  Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review.

Authors:  Per Gisle Djupesland
Journal:  Drug Deliv Transl Res       Date:  2012-10-18       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.